Zepbound (Tirzepatide) Injection – Chronic Weight Management

1. Indications & Approvals

buy Zepbound (Tirzepatide) Injection Pens – Chronic Weight Management

• Zepbound: Approved by the FDA (November 2023) for chronic weight management in adults who have:
  • A Body Mass Index (BMI) of ≥30 kg/m2\ge 30\ \text{kg/m}^2≥30 kg/m2 (obesity), or
  • A BMI of ≥27 kg/m2\ge 27\ \text{kg/m}^2≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
• Note: Must be used in conjunction with a reduced-calorie diet and increased physical activity.
• Mounjaro: Approved for improving glycemic control in adults with Type 2 Diabetes Mellitus.

---

2. Mechanism of Action (MOA)

Unlike single-receptor agonists such as semaglutide (Ozempic/Wegovy), which target only GLP-1, tirzepatide acts as a twin incretin mimetic:

1. GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Activation:
   • Modulates fat metabolism, improves insulin sensitivity in adipose tissue, and works synergistically with GLP-1 in the brain to reduce nausea and amplify satiety.
2. GLP-1 (Glucagon-Like Peptide-1) Receptor Activation:
   • Delays gastric emptying (slowing digestion).
   • Acts on hypothalamic appetite centers to decrease hunger and reduce cravings (“food noise”).
   • Stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion.

---

3. Efficacy: Key Clinical Findings (SURMOUNT Trials)

In the pivotal phase 3 SURMOUNT-1 trial (over 72 weeks in adults with obesity/overweight without diabetes):

• 5 mg/week: ~15.0% mean body weight reduction.
• 10 mg/week: ~19.5% mean body weight reduction.
• 15 mg/week: ~20.9% to 22.5% mean body weight reduction (average loss of roughly 52 lbs / 23.6 kg).
• Over one-third of participants on the highest dose lost $\ge 25\%$ of their body weight.

---

4. Dosing & Administration

• Method: Subcutaneous injection once weekly into the abdomen, thigh, or upper arm, at any time of day, with or without food.
• Titration Schedule:
  • Starting Dose: $2.5\text{mg}$ once weekly for 4 weeks (treatment initiation dose; not intended for weight reduction).
  • Escalation: Increase to $5\text{mg}$ weekly for at least 4 weeks.
  • Further Increases: If additional weight loss is needed and tolerated, dosage can increase in $2.5\text{mg}$ increments every 4 weeks.
  • Maintenance Doses: $5\text{mg}$, $10\text{mg}$, or $15\text{mg}$ weekly.
  • Maximum Dose: $15\text{mg}$ once weekly.

---

5. Adverse Effects & Safety Warnings

Common Side Effects (primarily gastrointestinal)

• Nausea (~25–30%)
• Diarrhea (~20%)
• Vomiting (~8–12%)
• Constipation (~11–17%)
• Dyspepsia (heartburn/indigestion) and abdominal pain
• Fatigue and injection-site reactions

(Gastrointestinal symptoms are most pronounced during dose escalation and typically subside over time.)

Critical Warnings & Contraindications

• Boxed Warning (Thyroid C-Cell Tumors): Contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis: Discontinue promptly if acute pancreatitis is suspected.
• Gallbladder Disease: Increased incidence of cholelithiasis (gallstones) and cholecystitis associated with rapid weight loss.
• Acute Kidney Injury: Usually secondary to dehydration from severe vomiting or diarrhea.
• Hypoglycemia: Risk is increased if used in combination with insulin or insulin secretagogues (e.g., sulfonylureas).
• Oral Contraceptive Interaction: Delayed gastric emptying can reduce the absorption of oral contraceptives. Patients taking oral birth control pills are advised to switch to a non-oral method or add a barrier method for 4 weeks after initiating treatment and for 4 weeks after each dose escalation.